Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.

24 Oct, 2022 | 14:01h | UTC

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network

 

Commentary on Twitter

 

ASCO Guideline | Treatment of metastatic colorectal cancer.

20 Oct, 2022 | 12:32h | UTC

Treatment of Metastatic Colorectal Cancer: ASCO Guideline – Journal of Clinical Oncology

Commentary: ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic CRC – ASCO Daily News

 

Commentary on Twitter

 

Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.

20 Oct, 2022 | 12:24h | UTC

Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations that Improve the Clinical Management of Pancreatic Cysts – Gastroenterology (PDF)

News Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh

 

Commentary from the author on Twitter (thread – click for more)

 

NCCN Guideline | Rectal cancer.

19 Oct, 2022 | 14:25h | UTC

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

 

Cohort Study | Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer.

17 Oct, 2022 | 12:14h | UTC

Incidence and Survival in Synchronous and Metachronous Liver Metastases From Colorectal Cancer – JAMA Network Open

 

15-year benefits of sigmoidoscopy screening on colorectal cancer incidence and mortality: a pooled analysis of randomized trials.

13 Oct, 2022 | 13:48h | UTC

15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality: A Pooled Analysis of Randomized Trials – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: One sigmoidoscopy significantly reduces long-term CRC incidence in both men and women – American College of Physicians

Related:

RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.

RCT: One-time flexible sigmoidoscopy screening is associated with long-term reduction in colorectal cancer incidence and mortality.

ACP Guideline: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults

BMJ Guideline: Colorectal Cancer Screening with Fecal Immunochemical Testing, Sigmoidoscopy or Colonoscopy

Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (if the link is paywalled, try this one in PMC)

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

 

Commentary on Twitter

 

RCT | Effect of colonoscopy screening on risks of colorectal cancer and related death.

11 Oct, 2022 | 13:42h | UTC

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

In gold-standard trial, invitation to colonoscopy reduced cancer incidence but not death – STAT

New study examines the effectiveness of colonoscopies – CNN

 

Podcast | Polyps, polypectomy & surveillance.

4 Oct, 2022 | 14:32h | UTC

Polyps, polypectomy & surveillance with Dr. Jennifer Maranki – The Curbsiders

 

Cohort Study | Adenoma detection rate after a positive FIT is linked to the risk of interval postcolonoscopy colorectal cancer.

4 Oct, 2022 | 14:31h | UTC

Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test–Based Screening: A Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentaries:

Colonoscopies in FIT-positive persons requires much higher ADR than primary colonoscopy – American College of Physicians – American College of Physicians

Adenoma Detection Rate Tied to CRC Risk After Positive FIT – HealthDay

 

Commentary on Twitter

 

Cohort Study | A clinical calculator for rectal cancer can estimate recurrence after neoadjuvant therapy with or without surgery.

30 Sep, 2022 | 12:34h | UTC

A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management – JAMA Network Open

Invited Commentary: A Clinical Calculator in the Era of Nonoperative Management for Rectal Cancer—How Should We Intensify or Deescalate Surveillance? – JAMA Network Open

 

Preliminary results of a RCT | Once-only colonoscopy vs. two rounds of fecal immunochemical testing 2 years apart for colorectal cancer screening.

20 Sep, 2022 | 13:29h | UTC

Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary: Two Rounds of FIT vs Single Colonoscopy as a One-time CRC Screening – Medscape (free registration required)

 

RCT | Short-term outcomes of laparoscopy-assisted vs. open surgery for patients with low rectal cancer.

16 Sep, 2022 | 12:58h | UTC

Short-term Outcomes of Laparoscopy-Assisted vs Open Surgery for Patients With Low Rectal Cancer: The LASRE Randomized Clinical Trial – JAMA Oncology

 

Commentary on Twitter

 

RCT | Robotic vs. laparoscopic surgery for middle and low rectal cancer.

15 Sep, 2022 | 13:09h | UTC

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentaries:

Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer — Randomized trial shows fewer positive circumferential resection margins with robotic technique – MedPage Today (free registration required)

 

Commentaries on Twitter

 

RCT | Extended duration thromboprophylaxis (continued for 56 days postoperatively) is not beneficial after surgical resection of colorectal cancer.

14 Sep, 2022 | 13:22h | UTC

Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial – The BMJ

 

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.

11 Sep, 2022 | 22:50h | UTC

AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma – Hepatology

 

RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.

8 Sep, 2022 | 14:24h | UTC

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial – Journal of Clinical Oncology

Editorial: Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine – Journal of Clinical Oncology

 

Commentary on Twitter

 

Single-arm, phase 2 study | Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

6 Sep, 2022 | 14:24h | UTC

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Addition of Galunisertib to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer – The ASCO Post

Improved Complete Response Rate Observed With Galunisertib Plus Neoadjuvant CRT in Advanced Rectal Cancer – Cancer Network

 

5-year follow-up of a RCT | Five-year outcomes of FOLFIRINOX vs. Gemcitabine as adjuvant therapy for pancreatic cancer.

5 Sep, 2022 | 14:26h | UTC

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

5 Sep, 2022 | 14:13h | UTC

Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease – Cochrane Library

Summary: How accurate are contrast-enhanced ultrasound scans for detecting hepatocellular carcinoma? – Cochrane Library

 

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score

2 Sep, 2022 | 13:03h | UTC

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score – ESMO Open

 

Single-arm phase 2 study | Neoadjuvant Nivolumab plus Ipilimumab and Adjuvant Nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma.

1 Sep, 2022 | 11:47h | UTC

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study – Journal of Clinical Oncology

 

Guideline | Fecal immunochemical testing in patients with signs or symptoms of suspected colorectal cancer.

31 Aug, 2022 | 11:52h | UTC

Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) – Gut

Commentary: Guidelines update: use of FIT in colorectal cancer referrals – PULSE

 

Meta analysis of randomized trials | Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer.

30 Aug, 2022 | 12:07h | UTC

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 

RCT | Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer.

30 Aug, 2022 | 11:58h | UTC

Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial – British Journal of Surgery

 

Cohort Study | Outcomes of patients with sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm under active surveillance.

30 Aug, 2022 | 11:57h | UTC

Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial – British Journal of Surgery

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.